CLOs on the Move

Asuragen

www.asuragen.com

 
"Asuragen has its roots in Ambion, ""The RNA Company."" Ambion is a molecular biology reagent company with a strong focus on RNA. Asuragen is the successor entity to Ambion. Ambion was formed in 1989 by Matt Winkler, then a University of Texas professor"
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Jenny Manuel
Vice President, General Counsel Profile

Similar Companies

ITR Laboratories Canada

ITR Laboratories Canada Inc. is a Baie-D'Urfí©, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Pacific Biolabs

Pacific Biolabs is a Hercules, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

New York Onclogy Hematology PC

New York Onclogy Hematology PC is a Latham, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Behavioral Health Sciences Institute

Behavioral Health Sciences Institute is a Portland, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NeoGenomics

NeoGenomics Laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. We work every day to achieve our common purpose of saving lives by improving patient CARE through Communication, Accuracy, Reliability, and Efficiency. Our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor FISH testing with the largest menu of technical-only services available; 10-color flow cytometry; IHC supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. Our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out FISH, flow cytometry, and/or IHC. NeoGenomics` extremely fast test development cycle means we are highly responsive to therapy development and guideline changes, and test design always involves a balance of convention and innovation.